Anavex Life Sciences Corp (AVXL)

[falconer66a]

For yet another CNS disease, blarcamesine works.

Peer Reviewed paper regarding Blarcamesine for the treatment of fragile X syndrome and other autism disorders.... https://www.researchsquare.com/article/rs-189177/v1

I read the paper, which described blarcamesine’s therapeutic effects on Fmr1 KO mouse models of fragile X syndrome. The results are summed in this statement: “When all 4 mouse groups were contrasted, chronic treatment with blarcamesine significantly reduced the behavior in Fmr1 KO2 mice to levels indistinguishable from those observed in vehicle-treated WT mice.”

Simply, the mice with fragile X syndrome genetics and behaviors, when treated with blarcamesine, lost the symptoms of the disease; they could not be distinguished from “WT mice,” wild-type mice, mice with normal genes, found in “wild” or normal mice.

Blarcamesine successfully treats fragile X syndrome in mice. Will it, then, do the same in humans with the disease? Of course, to be absolutely sure, the drug must be tested in humans with the disease. But the paper describes in detail the various mechanisms by which blarcamesine effected its favorable therapeutic outcomes. Inasmuch as the involved molecules and genetics in mice are those also in humans with the disease, there is no reason to think that the drug won’t be effective in humans.

The even greater question asks if blarcamesine might treat or prevent any or all of the various forms, spectra, of autism? This, too, must be affirmed in humans. But as with fragile X, there is a great likelihood of success. Should this be proven (in human clinical trials), let the reader discern the social, financial, and medical implications. Autism is a major health debility, diminishing the lives of millions.